Erythropoietin stimulating agents do not significantly improve quality of life in chronic kidney disease, study findsBMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i931 (Published 16 February 2016) Cite this as: BMJ 2016;352:i931
- Michael McCarthy,
Treating chronic kidney disease more intensively with erythropoietin stimulating agents (ESAs) to achieve higher haemoglobin levels did not improve patients’ quality of life, a meta-analysis published in the Annals of Internal Medicine has shown.1
ESAs are often used to raise haemoglobin levels in patients with chronic kidney disease, but optimal haemoglobin levels are debated, particularly because of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial